FDA Approves Jardiance To Treat Adults With Heart Failure

The U.S. Food and Drug Administration or FDA approved Boehringer Ingelheim's diabetes drug Jardiance (empagliflozin), co developed by Eli Lilly and Co., to mitigate the risk of cardiovascular death and hospitalization for heart failure in adults. Jardiance's approval was based on its safety and effectiveness that were evaluated as an adjunct to standard of care therapy in a randomized, double-blin

from RTT - Top Story https://ift.tt/O5fpJ1S
via IFTTT